EntryPoint Capital LLC Takes $423,000 Position in AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• EntryPoint Capital LLC invested approximately $423,000 in Amneal Pharmaceuticals, acquiring 50,530 shares in the company during the first quarter.
• Several institutional investors, including Janney Montgomery Scott LLC and Allspring Global Investments Holdings LLC, have significantly increased their positions in Amneal Pharmaceuticals, indicating growing institutional interest.
• Amneal Pharmaceuticals recently reported a quarterly earnings per share (EPS) of $0.23, outperforming analyst estimates and setting FY 2025 guidance at $0.700-$0.750 EPS.

EntryPoint Capital LLC bought a new position in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 50,530 shares of the company's stock, valued at approximately $423,000.

A number of other hedge funds and other institutional investors have also modified their holdings of AMRX. Vanguard Group Inc. increased its holdings in AMNEAL PHARMACEUTICALS by 6.2% in the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock valued at $132,092,000 after buying an additional 920,758 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in AMNEAL PHARMACEUTICALS by 5.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock valued at $39,531,000 after acquiring an additional 278,653 shares during the period. Nantahala Capital Management LLC boosted its stake in AMNEAL PHARMACEUTICALS by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock valued at $29,031,000 after acquiring an additional 995,586 shares during the period. Nuveen LLC acquired a new position in AMNEAL PHARMACEUTICALS in the first quarter valued at approximately $19,581,000. Finally, Invesco Ltd. boosted its stake in AMNEAL PHARMACEUTICALS by 19.2% in the first quarter. Invesco Ltd. now owns 2,272,713 shares of the company's stock valued at $19,045,000 after acquiring an additional 365,467 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

AMNEAL PHARMACEUTICALS Trading Up 0.6%

NASDAQ:AMRX traded up $0.06 during midday trading on Friday, hitting $9.59. 1,720,973 shares of the stock were exchanged, compared to its average volume of 1,697,029. AMNEAL PHARMACEUTICALS, INC. has a one year low of $6.68 and a one year high of $9.79. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of 959.96 and a beta of 1.11. The business has a 50-day moving average price of $8.38 and a two-hundred day moving average price of $8.01.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. Sell-side analysts forecast that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling at AMNEAL PHARMACEUTICALS

In other AMNEAL PHARMACEUTICALS news, EVP Jason B. Daly sold 22,000 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the sale, the executive vice president directly owned 10,606 shares of the company's stock, valued at $95,984.30. The trade was a 67.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrew S. Boyer sold 279,244 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the sale, the executive vice president directly owned 152,426 shares in the company, valued at approximately $1,429,755.88. This trade represents a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 456,374 shares of company stock valued at $4,239,042. Corporate insiders own 26.56% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on AMRX shares. The Goldman Sachs Group started coverage on AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 target price for the company. Wall Street Zen downgraded AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, AMNEAL PHARMACEUTICALS currently has an average rating of "Buy" and a consensus price target of $11.60.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.